<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03124160</url>
  </required_header>
  <id_info>
    <org_study_id>CCN016</org_study_id>
    <nct_id>NCT03124160</nct_id>
  </id_info>
  <brief_title>Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard</brief_title>
  <official_title>A Multi-center, Single-blind, Randomized Clinical Trial to Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Health Decisions</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>FHI 360 - IND Holder</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Health Decisions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a multi-site, participant-blinded, randomized clinical trial. The investigators
      will randomize 1000 eligible participants in a 4:1 ratio to two different copper IUDs: 800 to
      Mona Lisa NT Cu380 Mini and 200 to ParaGard.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total duration of the study for each participant is expected to be approximately 39
      months: including screening and enrollment (up to 30 days to meet enrollment criteria), 37
      months of participation, and a post-removal follow up telephone call 17 days post-removal.
      After enrollment, subject visits occur at 6 weeks, 3 months, 6 months, 12 months, 24 months,
      with telephone calls at 9, 18, and 30 months and seen again at 37 months for their final
      visit. Subjects will use a home pregnancy test 17 days post-removal of the IUD or Exit Visit
      procedures, whichever occurs first, and called by the site for the result and for safety
      follow-up.

      Subject recruitment is expected to begin Q2 (in the second quarter of) 2017 and is planned to
      continue through Q2 2018. However, if the enrollment rate declines, the enrollment period may
      be extended beyond this date. If this enrollment timeline is met, all subjects should finish
      active treatment by approximately the end of Q2 2021. The total duration of the study will be
      approximately 48 months for each study site including pre- and post- trial activities. The
      end of the study will occur when the last subject to be enrolled has completed her
      post-removal pregnancy test telephone call.

      Total duration of the project is expected to be five years. Preliminary results of the study
      are expected to be available Q4 of 2019 based on the current study plan.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2017</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy Rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>IUD continuation at months 12, 24 and 36 as measured by confirmation of IUD placement (visible or palpable)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failed IUD insertion as measured by inability to place the IUD correctly</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine perforation as measured by ultrasound</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IUD expulsion (complete and partial)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal bleeding patterns</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic pain as measured in the subject diary</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dysmenorrhea</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other side effects as measured by adverse and/or other events</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain with and shortly after insertion as measured by visual analog scale completed by study subjects</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of IUD insertion as measured by asking the investigator to assess ease of insertion</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall product satisfaction as measured by acceptability questions asked of subjects</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Healthy Women</condition>
  <condition>Female Contraception</condition>
  <arm_group>
    <arm_group_label>Mona Lisa® NT Cu380 Mini</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mona Lisa® NT Cu380 Mini containing 380mm2 of copper surface inserted into the uterine cavity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ParaGard® CuT380A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ParaGard® CuT380A containing 380mm2 of copper surface inserted into the uterine cavity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mona Lisa® NT Cu380 Mini</intervention_name>
    <description>Mona Lisa® NT Cu380 Mini</description>
    <arm_group_label>Mona Lisa® NT Cu380 Mini</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ParaGard® CuT380A</intervention_name>
    <description>ParaGard® CuT380A</description>
    <arm_group_label>ParaGard® CuT380A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  16-40 years

             o 16 and 17 year olds, where permissible by state regulations and local Institutional
             Review Board (IRB) approval

          -  Sexually active, anticipating at least one act of vaginal intercourse per menstrual
             cycle with a male partner and at risk for pregnancy

          -  seeking contraception, and willing to use the study IUD as the only contraception
             method

          -  willing to be randomized to one of the two copper IUDs

          -  has an intact uterus and at least one ovary

          -  has a history of regular menstrual cycles; defined as occurring every 21-35 days when
             not using hormones, and with a variation of typical cycle length of no more than 5
             days

          -  able and willing to provide written informed consent

          -  agrees to follow all study requirements

          -  not currently pregnant or at risk for luteal phase pregnancy based on history of
             unprotected intercourse

        Exclusion Criteria:

          -  abnormal Pap requiring treatment after enrollment

          -  known human immunodeficiency virus / acquired immunodeficiency syndrome (HIV/AIDS)
             infection

          -  intending to become pregnant in the 37 months after enrollment

          -  known infertility

          -  history of allergy or sensitivity to copper

          -  previous tubal sterilization

          -  has received an injectable contraceptive in the last 9 months and has not resumed
             regular menstrual cycles (as evidenced by 2 spontaneous menses)

          -  within 30 days of administration of mifepristone and/or misoprostol for medical
             abortion or for miscarriage management

          -  within 30 days of first, second, or third trimester abortion or miscarriage (note:
             potential abortion/miscarriage participants can be screened and return after 30 days
             for randomization and IUD insertion)

          -  within 30 days of delivery (for parous population)

          -  breastfeeding or recently breastfeeding women unless two consecutive normal menstrual
             periods have occurred after delivery and prior to enrollment.

          -  wants to use a copper IUD for emergency contraception

          -  has previously participated in the study

          -  participated in another clinical trial involving an investigational product within the
             last 30 days (before screening) or planning to participate in another clinical trial
             involving an intervention or treatment during this study

          -  not living in the catchment area of the study site or planning to move from the area
             within the year (unless known to be moving to the catchment area of another study
             site)

          -  known or suspected current alcohol or drug abuse

          -  planning to undergo major surgery during study participation

          -  current need for use of exogenous hormones or therapeutic anticoagulants (Note:
             subjects who start a therapeutic anticoagulant after enrolment will be allowed to
             continue in the study.)

          -  at high risk for sexually-transmitted infections or pelvic infection

          -  anticipated need for regular condom use (refer to Section 8.1).

          -  has any condition (social or medical) which in the opinion of the Investigator would
             make study participation unsafe or complicate data interpretation

          -  Reported medical contraindications (Medical Eligibility Criteria category 3 or 4)14 to
             copper IUDs, including:

               -  suspicious unexplained vaginal bleeding

               -  known cervical cancer

               -  known endometrial cancer

               -  known Wilson's disease

               -  Confirmed gestational trophoblastic disease with persistently elevated beta-hCG
                  levels or malignant disease, with evidence or suspicion of intrauterine disease

               -  anatomic abnormalities with distorted uterine cavity

               -  current pelvic inflammatory disease (PID)

               -  pelvic tuberculosis

               -  immediately post-septic abortion or puerperal sepsis

               -  current known purulent cervicitis or chlamydial infection or gonorrhea; Note: to
                  enroll, there must be no obvious signs of infection at the time of enrollment
                  based on pelvic exam. If lab results come back for positive infection after
                  enrollment, treatment should be provided but the IUD can be left in place.

               -  complicated solid organ transplantation

               -  systemic lupus erythematosus with severe thrombocytopenia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Blithe</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Child Health &amp; Human Development (NICHD)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Hubacher</last_name>
    <role>Study Director</role>
    <affiliation>FHI 360</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lesley Aycock</last_name>
    <phone>919-967-1111</phone>
    <phone_ext>231</phone_ext>
    <email>laycock@healthdec.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abbey Townsend</last_name>
    <phone>919-967-1111</phone>
    <phone_ext>308</phone_ext>
    <email>atownsend@healthdec.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Essential Access Health</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seline Guidotti</last_name>
      <email>sguidotti@essentialaccess.org</email>
    </contact>
    <investigator>
      <last_name>Anita Nelson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Overstreet</last_name>
      <phone>916-734-6227</phone>
      <email>cboverstreet@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Mitchell Creinin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abby Sokoloff</last_name>
      <email>sokoloffa@obgyn.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Philip Darney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ines Crato</last_name>
      <email>ines.crato@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Stephanie Teal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiana Fontanilla</last_name>
      <phone>808-203-6594</phone>
      <email>tfontanilla@ucera.org</email>
    </contact>
    <investigator>
      <last_name>Bliss Kaneshiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Thaler</last_name>
      <phone>410-550-8506</phone>
      <email>kstouff3@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Anne Burke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center Corporation</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Remis</last_name>
      <email>kimberly.remis@bmc.org</email>
    </contact>
    <investigator>
      <last_name>Katharine White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood League of Massachusetts</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alisa Goldberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Porsch</last_name>
      <phone>212-274-7340</phone>
    </contact>
    <investigator>
      <last_name>Ila Dayananda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Roca</last_name>
      <phone>212-342-2986</phone>
      <email>cr479@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Paula Castano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Boerschig</last_name>
      <phone>513-584-5361</phone>
      <email>debbie.boerschig@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Holt</last_name>
      <phone>503-494-3666</phone>
      <email>holte@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Jensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arden McAllister</last_name>
      <email>Arden.Mcallister@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Courtney Schreiber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Beatrice Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Orr</last_name>
      <phone>801-213-2774</phone>
      <email>amy.orr@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>David Turok, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Evans</last_name>
      <phone>757-446-7972</phone>
      <email>evansjl@evms.edu</email>
    </contact>
    <investigator>
      <last_name>David Archer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018680s066lbl.pdf</url>
  </link>
  <reference>
    <citation>Sivin I, Stern J. Long-acting, more effective copper T IUDs: a summary of U.S. experience, 1970-75. Stud Fam Plann. 1979 Oct;10(10):263-81.</citation>
    <PMID>516121</PMID>
  </reference>
  <reference>
    <citation>Sivin I, Tatum HJ. Four years of experience with the TCu 380A intrauterine contraceptive device. Fertil Steril. 1981 Aug;36(2):159-63.</citation>
    <PMID>7262334</PMID>
  </reference>
  <reference>
    <citation>Sivin I, Stern J, Coutinho E, Mattos CE, el Mahgoub S, Diaz S, Pavez M, Alvarez F, Brache V, Thevenin F, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. Contraception. 1991 Nov;44(5):473-80.</citation>
    <PMID>1797462</PMID>
  </reference>
  <reference>
    <citation>The TCu380A, TCu220C, multiload 250 and Nova T IUDS at 3,5 and 7 years of use--results from three randomized multicentre trials. World Health Organization. Special Programme of Research, Development and Research Training in Human Reproduction: Task Force on the Safety and Efficacy of Fertility Regulating Methods. Contraception. 1990 Aug;42(2):141-58.</citation>
    <PMID>2085966</PMID>
  </reference>
  <reference>
    <citation>Hubacher D. Copper intrauterine device use by nulliparous women: review of side effects. Contraception. 2007 Jun;75(6 Suppl):S8-11. Epub 2007 Feb 20. Review.</citation>
    <PMID>17531622</PMID>
  </reference>
  <reference>
    <citation>Abraham M, Zhao Q, Peipert JF. Young Age, Nulliparity, and Continuation of Long-Acting Reversible Contraceptive Methods. Obstet Gynecol. 2015 Oct;126(4):823-9. doi: 10.1097/AOG.0000000000001036.</citation>
    <PMID>26348177</PMID>
  </reference>
  <reference>
    <citation>Benacerraf BR, Shipp TD, Lyons JG, Bromley B. Width of the normal uterine cavity in premenopausal women and effect of parity. Obstet Gynecol. 2010 Aug;116(2 Pt 1):305-10. doi: 10.1097/AOG.0b013e3181e6cc10.</citation>
    <PMID>20664389</PMID>
  </reference>
  <reference>
    <citation>Koch P, Reinhardt P, Soyka E. Intrauterine contraception using the Copper Mini-Gravigard 7 IUD: summary of 328 case histories. Contracept Deliv Syst. 1981 Apr;2(1):171-6.</citation>
    <PMID>12336868</PMID>
  </reference>
  <reference>
    <citation>Petersen KR, Brooks L, Jacobsen N, Skoby SO. Clinical performance of intrauterine devices in nulligravidae: is the length of the endometrial cavity of significance? Acta Eur Fertil. 1991 Jul-Aug;22(4):225-8.</citation>
    <PMID>1844327</PMID>
  </reference>
  <reference>
    <citation>Otero-Flores JB, Guerrero-Carreño FJ, Vázquez-Estrada LA. A comparative randomized study of three different IUDs in nulliparous Mexican women. Contraception. 2003 Apr;67(4):273-6.</citation>
    <PMID>12684147</PMID>
  </reference>
  <reference>
    <citation>Ott MA, Sucato GS; Committee on Adolescence. Contraception for adolescents. Pediatrics. 2014 Oct;134(4):e1257-81. doi: 10.1542/peds.2014-2300. Review.</citation>
    <PMID>25266435</PMID>
  </reference>
  <reference>
    <citation>Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists. Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2012 Oct;120(4):983-8.</citation>
    <PMID>22996129</PMID>
  </reference>
  <reference>
    <citation>Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, Simmons KB, Pagano HP, Jamieson DJ, Whiteman MK. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep. 2016 Jul 29;65(3):1-103. doi: 10.15585/mmwr.rr6503a1.</citation>
    <PMID>27467196</PMID>
  </reference>
  <reference>
    <citation>Heinemann K, Reed S, Moehner S, Minh TD. Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices. Contraception. 2015 Apr;91(4):274-9. doi: 10.1016/j.contraception.2015.01.007. Epub 2015 Jan 16.</citation>
    <PMID>25601352</PMID>
  </reference>
  <reference>
    <citation>Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 1992 Mar 28;339(8796):785-8.</citation>
    <PMID>1347812</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Women</keyword>
  <keyword>Female Contraception</keyword>
  <keyword>IUD</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Copper</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

